03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
18:00 , Jan 11, 2019 |  BC Week In Review  |  Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Jan. 4 it...
19:43 , Jan 6, 2019 |  BC Extra  |  Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will...
01:28 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
23:42 , Dec 5, 2018 |  BC Extra  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product...
21:41 , Aug 10, 2018 |  BioCentury  |  Finance

Wnt to market

With no traditional life science VCs in its syndicate and little publicly disclosed about its science, Samumed LLC was able to raise a $438 million round at a premoney valuation of $12 billion, bringing its...
18:48 , Apr 20, 2018 |  Regulatory  |  Regulatory

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
22:51 , Apr 18, 2018 |  BC Extra  |  Company News

Opdivo gets Priority Review for third-line SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted and granted Priority Review to an sBLA for Opdivo nivolumab to treat small cell lung cancer in patients whose disease has progressed after two or more prior therapies....
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke...